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ABSTRACT
Introduction: The elderly are at high risk of 
severe seasonal influenza and influenza-related 
death. Annual vaccination can effectively 
prevent influenza and its complications, and 
is recommended in the elderly. In the present 
study, surveys were undertaken in France and 
Germany to determine whether INTANZA®
(sanofi pasteur, Val-de-Reuil, France), the first 
intradermal influenza vaccine, administered 
using an innovative microneedle injection 
system, might influence physicians’ likelihood 
of recommending influenza vaccination or the 
likelihood that the general public would seek 
influenza vaccination. Methods: Physicians 
(France: n=260; Germany: n=223) and members 
of the general public aged ≥50 years (France: 
n=1706; Germany: n=1072) completed online 
surveys. Details of the INTANZA delivery 
system, and a “product profile” based on 
the properties of INTANZA, were presented. 
Results: Most physicians and the general 
public found INTANZA and its microneedle 
injection system appealing. The main benefit 
of INTANZA, as perceived by physicians and 
the public, was the small needle size. Physicians 
also found the high immunogenicity compared 
with conventional intramuscular (IM) vaccines 
attractive. The majority of physicians believed 
that INTANZA would strongly help them to 
recommend vaccination to their unvaccinated 
patients (66% to 91%, depending upon patient 
characteristics); most (61% to 78%) would prefer 
to prescribe INTANZA rather than an IM vaccine. 
More than two-thirds of the unvaccinated 
general public would prefer INTANZA over IM 
vaccines, and the option of vaccination with 
INTANZA would encourage a large proportion 
of them to get vaccinated (60% to 74%), if it 
was recommended and they were given the 
choice. Physicians (≥82%) agreed that INTANZA 
may help increase vaccination coverage rates. 
Conclusion: The results of these surveys indicate 
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that the availability of INTANZA may encourage 
physicians to recommend influenza vaccination, 
and members of the general public to get 
vaccinated. INTANZA may help to improve 
seasonal influenza vaccination coverage rates.
Keywords: INTANZA; intradermal influenza 
vaccine; microneedle injection system; survey; 
vaccination coverage rate; willingness to 
vaccinate/get vaccinated 
INTRODUCTION
Although seasonal influenza is sometimes 
perceived as a mild infection, it can cause severe 
illness and death.1 Indeed, it is estimated that 
deaths from seasonal influenza in the European 
Union (EU) range from 40,000 in a mild season, 
to 220,000 in a moderate-to-severe season.2
Approximately 90% of influenza-associated 
deaths occur in individuals aged ≥65 years.3
Annual vaccination effectively prevents 
seasonal influenza and its complications.1 The 
World Health Organization (WHO) and the 
council for the EU have set targets for seasonal 
influenza vaccination coverage of ≥75% of 
the elderly (aged ≥65 years)4,5 and those with 
chronic medical conditions.5 All Western 
European countries recommended influenza 
vaccination for these populations.6 In the 
2007/8 influenza season, vaccination coverage 
was slightly less than 65% in France and just 
over 60% in Germany among individuals for 
whom vaccination is recommended (those 
aged ≥65 years in France and ≥60 years in 
Germany).7 It is clear that further efforts are 
required to reach the ≥75% seasonal influenza 
vaccination coverage rate in these target 
groups.4,5 Consequently, it is important to 
evaluate any potential initiatives that may 
help to increase individuals’ willingness to get 
vaccinated against influenza. 
INTANZA ® (sanof i  pasteur,  Val -de-
Reuil, France), the first intradermal (ID) 
influenza vaccine, is administered using 
an innovative, reliable, and easy-to-use 
microneedle injection. It provides high 
seroprotection by targeting the dermis,8,9 a 
highly immunogenic area.10,11 The dermis 
has a high density of lymphatic and blood 
capillary vessels, facilitating direct contact 
between administered antigens and the 
immune system.11 Hence, ID immunization 
triggers synergistic pathways thus amplifying 
the immune response.11
INTANZA is available in two doses to 
meet the seasonal vaccination requirements 
of different adult age groups.12 INTANZA 15 
contains 15 µg hemagglutinin (HA) for each 
of three influenza strains, and is intended for 
use in individuals aged ≥60 years in whom 
influenza vaccinations are generally less 
effective.13 Clinical studies have shown that 
this vaccine provides antibody responses (and 
seroprotection) superior to those seen with 
conventional intramuscular (IM) vaccination 
in adults aged ≥60 years.9 INTANZA 9,
which contains 9 µg HA for each of three 
influenza strains, is intended for use in adults 
aged <60 years,8,14 and has been shown to be 
as immunogenic as conventional IM seasonal 
influenza vaccine.8 Both formulations are 
well tolerated, and injection-site reactions are 
transient and generally mild.8,9
The authors attempted to evaluate whether 
the availability of INTANZA and its microneedle 
injection system might influence physicians’ 
likelihood of recommending influenza 
vaccination or the likelihood that the general 
public would seek influenza vaccination, thereby 
encouraging influenza vaccination uptake. 
Surveys of physicians, and of the general public 
aged ≥50 years, were conducted in France and 
Germany. 
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MATERIALS AND METHODS
Survey 
Physicians and members of the general public 
in France and Germany were asked to complete 
an online questionnaire during July 15 to 
July 27 (physicians) and July 15 to August 15 
(general public) of 2009. Participants responding 
‘I do not agree at all’ to any of the following 
statements were considered as not being in 
favor of vaccination in general, or seasonal 
influenza vaccination specifically: vaccination 
against certain diseases is important for healthy 
living and the prevention of serious illnesses 
(all participants); I actively encourage flu 
vaccination (physicians); or I consider a flu 
vaccination useful for people aged ≥50 (general 
public). These individuals were identified during 
the screening process and excluded from the 
analysis. 
Details of the microneedle injection system 
by which INTANZA is delivered (Figure 1) and a 
“product profile” for a new ID seasonal influenza 
vaccine, described as product X (INTANZA), 
based on a summary of INTANZA 9 and 
INTANZA 15 summary of product characteristics 
and clinical trial data,8,9,15 were presented. The 
“product profile” was adapted for the general 
public and a combination of the characteristics 
of INTANZA 9 and INTANZA 15 was presented. 
Participants were informed that “product X” 
would be recommended and reimbursed in the 
same way as conventional IM seasonal influenza 
vaccines. 
Three assessments were undertaken based 
on the information presented: the general 
impressions and appeal of INTANZA; preference 
between ID administration with INTANZA and 
conventional IM influenza vaccination; and the 
willingness of physicians to vaccinate new patients 
with INTANZA for the next influenza season, or 
willingness of members of the general public to be 
vaccinated with INTANZA for the next influenza 
season. Appeal was assessed using a five-point scale: 
“very appealing,” “appealing,” “not appealing,” 
“not appealing at all,” and “don’t know”. 
Physicians’ belief about whether INTANZA 
Figure 1. The INTANZA microneedle injection system compared with the conventional intramuscular influenza vaccine 
delivery method.
INTANZA® microneedle injection system
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would help them recommend seasonal 
influenza vaccination was measured on a 
five-point scale: “very strongly,” “strongly,” 
“not strongly,” “not strongly at all,”
and “don’t know”. A five-point scale was also 
used to assess whether physicians were likely to 
prescribe INTANZA to their patients: “very likely,” 




Physicians were recruited from a European 
panel of family physicians with >15,000 
members. Those with between 3 and 35 
years’ experience and who administered and/
or prescribed seasonal influenza vaccines 
were eligible to participate in the survey if 
≥20% of their patients were >60 years of age. 
Representativeness among physicians was 
achieved by applying specific quotas on age, 
gender, and regional spread.
General Public
Members of the general public were recruited 
from a consumer panel with 25,000 members 
in France and 27,000 members in Germany. 
Individuals aged 50 to 69 years were eligible to 
participate in the survey in France, and those 
aged 50 to 65 years were eligible to participate 
in Germany. Members of the general public 
were invited to participate in the survey and 
then made the decision to complete the survey 
on-line, thus implying their consent. Quotas 
on gender, age, region, social class (France), or 
monthly household income (Germany) were 
applied to obtain representative samples of the 
general public in France and Germany, referred 
to herein as the “average population”.
Additional samples were recruited for 
those aged ≥60 years in France and Germany 
to ensure there were sufficient sample sizes 
for those groups covered by the age-based 




A representative sample of physicians from France 
(n=260) and Germany (n=223) completed the online 
survey. Of those participating, 45% of the French 
physicians and 40% of the German physicians 
practiced in towns with <20,000 inhabitants.
A total of 7150 members of the general 
public were invited to participate in the survey. 
Of these, 76.79% accepted the invitation and 
50.60% completed the online questionnaire. 
In total, 1706 members of the general public in 
France and 1072 members of the general public 
in Germany completed the survey. Distribution 
data for members of the general public who 
participated can be found in Table 1.
Physicians
Appeal, Preference, and Likelihood of 
Prescribing INTANZA 
A very high proportion of physicians rated the 
characteristics of both INTANZA 9 and INTANZA 
15 with its microneedle injection system as 
appealing (“very appealing” plus “appealing”). 
INTANZA 9 appealed to 87% of physicians in 
France and to 94% in Germany, and INTANZA 
15 appealed to 94% and 91% of physicians in 
France and Germany, respectively. 
The majority of physicians in both France 
and Germany believed that INTANZA 9 and 
INTANZA 15 would strongly help them to 
recommend seasonal influenza vaccination to 
unvaccinated patients (ie, those who were not 
vaccinated for the previous influenza season), 
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particularly those averse to injections (Figure 2).
The majority of physicians would also prefer 
to prescribe INTANZA over a conventional IM 
influenza vaccine. In France and Germany, 
respectively, INTANZA 9 was preferred by 73% 
and 61% of physicians whilst 78% and 63% of 
physicians preferred to prescribe INTANZA 15 
versus conventional IM therapy. 
Almost all physicians stated that they were 
likely (ie, “very likely” plus “likely”) to prescribe 
INTANZA 15 to those patients covered by the 
national age-based recommendations, and 
those averse to needles (Figure 3). Physicians 
were also likely to prescribe INTANZA 9 to 
patients aged 18 to 59 years with and without 
risk factors, and to those averse to needles 
(Figure 3).
Benefits of INTANZA
Physicians perceived the main benefits of 
INTANZA to be its immunogenicity and 
seroprotection rates compared with conventional 
IM vaccines, in addition to the small needle size 
leading to a less painful or pain-free injection 
(Table 2). It should be noted that physicians’ 
answers were spontaneous (ie, the physicians 
had the freedom to write their own responses), 
and the answers do not necessarily reflect the 
characteristics of INTANZA incorporated within 
the “product profile” presented.
France Germany
Total (n) 
   Average population* 
   Additional samples†
Age range (years) 
   50-59  
   60-64  
      Average population* 
      Additional samples† 
   65-69 years 
      Average population* 
      Additional sample†
Vaccinated/unvaccinated (average population)* 
   Vaccinated 
   Unvaccinated‡
Covered by age-based recommendations and reimbursement§ 
   Vaccinated 
   Unvaccinated‡
Working population|| (average population)* 
   Vaccinated 









































*Average population is the representative sample of people aged 50-69 years in France and aged 50-64 years in Germany, with 
the same age distribution among that age range as the general population.  
†Additional representative samples were recruited to ensure sufficient sample sizes for those groups covered by the age-based 
recommendations. 
‡Not vaccinated in the previous influenza season (2008/9). 
§Seasonal influenza vaccination is recommended and reimbursed for those aged ≥65 years in France and those aged ≥60 
years in Germany (average population and additional samples included for the valid age groups).  
||Working age population in France: aged 50-64 years, Germany: aged 50-59 years (average population).
Table 1. Distribution of the general public who participated in the survey.
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Figure 2. Percentage of physicians who believe INTANZA would help them to strongly recommend* seasonal influenza 
vaccination to unvaccinated patients† (France: n=260; Germany: n=223). “Very strongly” or “strongly” on a five-point scale 
including “not strongly,” “not strongly at all,” and “I don’t know.”* Those not vaccinated for the previous influenza season 
(2008/9).†
Figure 3. Percentage of physicians who were likely to prescribe* INTANZA to their patients (France: n=260; Germany: 
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The majority of physicians agreed with the 
statement, “This vaccine may help increase 
flu vaccination coverage rates as it will be well 
accepted by patients”. In total, 82% of French 
physicians and 85% of German physicians agreed 
that INTANZA 9 could increase vaccination 
coverage rates, and 83% and 87% of French and 
German physicians, respectively, believed that 
INTANZA 15 could improve coverage rates. 
General Public 
The vast majority of the general public surveyed 
found INTANZA and its micro-injection system 
appealing (“very appealing” plus “appealing”). 
In France, 91% of the average population found 
INTANZA appealing, along with 90% of those 
covered by the age-based recommendations. 
Similarly, in Germany, 90% of the average population 
found INTANZA appealing, along with 91% of those 
covered by the age-based recommendations.
More than two in three members of the general 
public surveyed who were not vaccinated for 
the previous influenza season (“unvaccinated”) 
would prefer to receive INTANZA over a 
conventional IM injection, if vaccination was 
recommended by their physician and they 
were given the choice (Figure 4). Indeed, a 
large proportion of the unvaccinated general 
public declared that the option of vaccination 
with INTANZA would encourage them to be 
vaccinated in the future, if it was recommended 
by their physician (Figure 4). Many of the 
unvaccinated public believed that the ID route 
of administration of INTANZA would reduce the 
degree of apprehension associated with annual 
influenza vaccination (France: 82%; Germany: 
60%; average populations). Furthermore, in 
response to the question: “Do you think that 
the smaller needle size of the new seasonal flu 
vaccine would lower your fear of needles?” many 
participants’ felt that the microneedle injection 
Table 2. The benefits of INTANZA as perceived by family physicians and the general public (average population*).†
Family physicians General public















Small/short needle 40 31 32 23 31 23
Small volume 24 4 19 4 12 9
High/higher immunogenicity (family physicians)/protection 













Less painful/pain free 17 14 17 10 17 10
More effective/better efficacy 11 6 14 13 6 12
Easy to use/more practical 10 12 10 10 8 6
Intradermal administration (family physicians), directly 













Well tolerated/fewer side effects 7 5 9 5 22 34
Avoids fear of needles 6 10 6 9 7 7
*Average population is the representative sample of people aged 50-69 years in France and aged 50-64 years in Germany. 
†Answers were spontaneous (and are paraphrased) and do not necessarily reflect the characteristics of INTANZA 
incorporated within the “product profile”’ presented. 
‡INTANZA 9 and 15 for family physicians, respectively.
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system would reduce their fear: 85% and 83% 
of those participants in France and Germany, 
respectively, who were averse to needles (average 
populations: n=226 and n=103).
In addition to those unvaccinated for 
the previous season, 75% and 71% of the 
average populations who were vaccinated for 
the previous influenza season in France and 
Germany, respectively, would prefer to receive 
INTANZA rather than the conventional IM 
injection for the next influenza season, if it was 
recommended by their physician and they were 
given the choice.
The general public perceived the main 
benefits of INTANZA to be the small needle 
size and ID administration (Table 2; as with 
physicians, members of the general public were 
free to write their own responses).
DISCUSSION
These surveys indicate that the availability of 
INTANZA, the first ID seasonal influenza vaccine 
to be licensed, would encourage physicians to 
recommend seasonal influenza vaccination 
to their patients. Most physicians stated a 
preference for INTANZA over conventional 
IM vaccination. Physicians perceived the 
main benefits of INTANZA to be related to the 
small/short needle and high immunogenicity 
of the vaccine. Furthermore, INTANZA is 
highly acceptable to the general public, and 
its availability would encourage vaccination, 
even in those who were not vaccinated for the 
previous influenza season.
In addition to the well-established patient 
barriers to seasonal influenza vaccination, 
Figure 4. Percentage of the unvaccinated* general public who would prefer to receive INTANZA (compared with the 
conventional intramuscular vaccine), and who would be encouraged to get vaccinated† by the availability of INTANZA. 
Those who were not vaccinated for the previous influenza season (average population).* “Strongly encouraged” plus 
“encouraged” on a five-point scale that also included “not encouraged”, “not encouraged at all”, and “don’t know”.† Those who 
were not vaccinated for the previous influenza season but in whom vaccination is recommended based on age (France: ≥65 





































































n=774 n=486 n=187 n=264 n=686 n=372 n=774 n=188 n=187 n=264 n=686 n=372
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such as the belief that healthy people do not 
need vaccinations and family physicians not 
recommending influenza vaccination,16 other 
barriers relate to the acceptability of the vaccine 
itself.16-18 Indeed, in Europe, 25% of the elderly 
expressed concern over the possible side effects 
of vaccination,17 and 14% stated that they did 
not like injections or needles.18 In the current 
surveys, 19% (n=226) of the average general 
public surveyed in France and 13% (n=103) 
of those surveyed in Germany reported being 
averse to needles.
The results of this survey indicate that 
INTANZA and its microneedle injection system 
would increase the uptake of seasonal influenza 
vaccine by reducing fear of vaccination in the 
vast majority of those averse to needles. In a 
European survey across five European countries, 
24% of those surveyed (n~10,000) stated that 
alternative ways of administration would 
encourage them to be vaccinated.18
The acceptability of ID INTANZA vaccination 
to the general public seen in these surveys 
reflects its acceptability in >5000 individuals 
who received ID vaccination with INTANZA 
in the European phase 3 studies.15 In these 
studies, 2098 individuals aged 18 to 60 
years (adults) and 3207 individuals aged >60 
years (elderly) received INTANZA. Almost all 
individuals were “very satisfied” or “satisfied” 
with the ID microneedle injection system 
(96% for both adults and elderly), with a vast 
majority stating that they would “definitely” 
or “probably” want to be vaccinated using 
this administration system for the following 
influenza season (85% of adults and 89% of the 
elderly).15 Furthermore, the observed reduction 
in the degree of apprehension with INTANZA 
compared with IM vaccination also reflects the 
responses of individuals enrolled in the phase 
3 studies.15 In these studies, 76% of adults and 
89% of the elderly stated that they were not at 
all anxious about receiving INTANZA; 90% to 
91% of individuals who were vaccinated stated 
that they were not at all anxious about receiving 
vaccination the following year.15
The results of these surveys indicate 
that the availability of INTANZA would 
encourage individuals aged ≥50 years who 
did not receive seasonal influenza in the 
previous year to get vaccinated in the future, 
including those covered by the national age-
based recommendations and the working- 
age population (France: 50-64 years old; 
Germany: 50-59 years old). Encouraging more 
individuals covered by national age-based 
recommendations to have annual seasonal 
influenza vaccinations would ensure progress 
towards the achievement of the WHO/EU 
targets for seasonal influenza vaccination.4,5
In addition to the direct healthcare costs 
associated with seasonal influenza individuals 
≥50 years, improving vaccination coverage 
in this group will reduce lost productivity. 
Indeed, increasing vaccination coverage has the 
potential to reduce lost work days.19
These surveys have several limitations: the 
surveys were theoretical, as the participants based 
their responses on information they received 
about INTANZA, rather than experience of using 
or receiving it. A future survey of this nature 
would be implemented by including groups 
of participants who had undergone influenza 
vaccination with INTANZA. The implied 
improvement in vaccination coverage requires 
confirmation by investigating prospectively the 
effect of introducing INTANZA. 
CONCLUSION
In summary, the results of these surveys indicate 
that ID vaccination with INTANZA is appealing 
to both physicians and the general public. Most 
physicians expressed willingness to prescribe 
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INTANZA, and the availability of this vaccine 
would encourage them to recommend seasonal 
influenza vaccination to their patients. Also, 
the general public appeared to prefer INTANZA 
over conventional IM vaccination, with reduced 
apprehension attributable to the microneedle 
injection system. The availability of INTANZA 
would encourage unvaccinated members of 
the general public, including both the working 
population and those covered by national age-
based recommendations, to be vaccinated. 
Ultimately, the findings of this study imply 
that the majority of physicians consider that 
INTANZA may help progress towards attainment 
of the WHO/EU targets for vaccination coverage.
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